Visceral fat deposition and insulin sensitivity in depressed women with and without comorbid borderline personality disorder

Psychosomatic Medicine

Volumn 67, Issue 3, 2005, Pages 407-412

  Kahl, Kai G ^a   Bester, Maxim ^a   Greggersen, Wiebke ^a   Rudolf, Sebastian ^a   Dibbelt, Leif ^a   Stoeckelhuber, Beate M ^a   Gehl, Hans Björn ^b   Sipos, Valerija ^a   Hohagen, Fritz ^a   Schweiger, Ulrich ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Universität zu Lübeck ^*

Author keywords

Borderline personality disorder; Hypothalamic pituitary adrenal system; Interleukin 6; Major depressive disorder; Tumor necrosis factor

Indexed keywords

CYTOKINE; HYDROCORTISONE; INSULIN; INTERLEUKIN 6; SEROTONIN UPTAKE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BORDERLINE STATE; CALCULATION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DEPRESSION; ENDOCRINE SYSTEM; FEMALE; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LUMBAR VERTEBRA; MAJOR DEPRESSION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; VISCERAL FAT DEPOSITION;

ADULT; BORDERLINE PERSONALITY DISORDER; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; HOMEOSTASIS; HUMANS; HYDROCORTISONE; INSULIN RESISTANCE; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MAGNETIC RESONANCE IMAGING; MODELS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21144448323     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.psy.0000160458.95955.f4     Document Type: Article

References (42)

1. Mueller PS, Heninger GR, McDonald RK. Intravenous glucose tolerance test in depression. Arch Gen Psychiatry 1969;21:470-7.
2. Winokur A, Maislin G, Phillips JL, Amsterdam JD. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry 1988;145:325-30.
3. Glassmann AH, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4-11.
4. Musselmann DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes type 1 and 2: epidemiology, biology and treatment. Biol Psychiatry 2003;54:317-29.
5. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003;54:227-40.
6. Williams SA, Kasl SV, Heiat A, Abramson JL, Krumholz HM, Vaccarino V. Depression and risk of heart failure among the elderly: a prospective community-based study. Psychosom Med 2002;64:6-12.
7. Björntorp P. The association between obesity, adipose tissue distribution and disease. Acta Med Scand 1987;723:121-34.
8. Thakore JH, Richards PJ, Reznek RH, Martin A, Dinan TG. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computer tomography. Biol Psychiatry 1997;41:1140-2.
9. Weber-Hamann B, Hentschel F, Kniest A, Deuschle M, Colla M, Lederbogen F, Heuser I. Hypercortisolemic depression is associated with increased intra-abdominal fat. Psychosom Med 2002;64:274-7.
10. Wajchenberg LB. Subcutaneous and visceral adipose tissue. Their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
11. Carroll BJ, Greden JF, Feinberg M, Lohr N, James NM, Steiner M, Haskett RF, Albala AA, DeVigne JP, Tarika J. Neuroendocrine evaluation of depression in borderline patients. Psychiatr Clin North Am 1981; 4:89-99.
12. De la Fuente JM, Mendlewicz J. TRH stimulation and dexamethasone suppression in borderline personality disorder. Biol Psychiatry 1996;40: 412-8.
13. Heuser I. The hypothalamic-pituitary-adrenal axis in depression. Pharmacopsychiatry 1998;31:10-13.
14. Lahmeyer HW, Reynolds CF, Kupfer DJ, King R. Biologic markers in borderline personality disorder: a review. J Clin Psychiatry 1989;50: 217-25.
15. Corruble E, Ginestet D, Guelfi JD. Comorbidity of personality disorders and unipolar major depression: a review. J Affect Disord 1996;37: 157-70.
16. Rossi A, Marinangeli MG, Butti G, Scinto A, Di Cicco L, Kalyvoka A, Petruzzi C. Personality disorders in bipolar and depressive disorders. J Affect Disord 2001;65:3-8.
17. Godfrey KM, Barker DJP. Fetal nutrition and adult disease. Am J Clin Nutr 2000;1344S-52S
18. Plotsky PM, Meaney MJ. Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology 1993;137:1212-8.
19. Vickers MH, Reddy S, Ikenasio BA, Breier BH. Dysregulation of the adipoinsular axis-a mechanism for the pathogenesis of hyperleptinemia and adipogenic diabetes induced by fetal programming. J Endocrinol 2001;170:323-32.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
21. Maes M. Major depression and activation of the inflammatory response syndrome. Adv Exp Med Biol 1999;461:25-46.
22. Dantzer R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression: fortuitous or causative association? Mol Psychiatry 1999;4: 328-32.
23. Nilsson J, Jovinge S, Niemann A, Reneland R, Lithell H. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998;18:1199-1202.
24. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40: 1286-92.
25. Seidell JC, Bakker CJ, van der Kooy K. Imaging techniques for measuring adipose tissue distribution-a comparison between computed tomography and 1.5-T magnetic resonance. Am J Clin Nutr 1990;51:953-7.
26. van der Kooy K, Seidell J. Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 1993;17:187-96.
27. Conwell LS, Trost SG, Brown WJ, Batch JA. Indexes of insulin resistance and secretion in obese children and adolescents: a validation study. Diabetes Care 2004;27:314-9.
28. Hermans MP, Levy JS, Morris RJ, Turner RC. Comparison of tests of -cell function across a range of glucose tolerance from normal to diabetes. Diabetes 1999;48:1779-86.
29. Rebuffé-Scrive M, Walsh UA, McEwen B, Rodin J. Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiol Behav 1992;52:583-90.
30. Rebuffé-Scrive M, Bronnegard M, Nilsson A, Eldh J, Gustafsson J, Björntorp P. Steroid hormone receptors in human adipose tissue. J Clin Endocrinol Metab 1990;71:1215-9.
31. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003;160:1554-65.
32. Vicennati V, Vottero A, Friedman C, Papanicolaou DA. Hormone regulation of interleukin-6 production in human adipocytes. Int J Obesity 2002;26:905-11.
33. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW. Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 2003;29:423-47.
34. Weber B, Schweiger U, Deuschle M, Heuser I. Major depression and impaired glucose tolerance. Exp Clin Endocrinol Diabetes 2000;108: 187-90.
35. Björntorp P. Metabolic implications of fat distribution. Diabetes Care 1991;14:1132-43.
36. Després J-P. Health consequences of visceral obesity. Ann Med 2001; 33:534-41.
37. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
38. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor-alpha inhibits signalling from the insulin receptor. Proc Natl Acad Sci U S A 1994(a);91:4854-8.
39. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor-alpha: a key component of the obesity-diabetes link. Diabetes 1994(b);43:1271-8.
40. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78.
41. Jaattela M. Biological activities and mechanisms of action of tumor necrosis factor-alpha/cachectin. Lab Invest 1991;64:724-42.
42. Bendtzen K, Buschard K, Diamant M, Horn T, Svenson M. Possible role of IL-1, tumor necrosis factor-alpha and IL-6 in insulin-dependent diabetes mellitus and autoimmune thyroid disease. Lymphokine Res 1989; 8:335-41.